Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10596160 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
A novel GPR119 agonist based on the 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole scaffold was designed through lead optimization starting from pyrazole-based GPR119 agonist 1. The design is centered on the conformational restriction of the core scaffold, while minimizing the change in spatial relationships of two key pharmacophoric elements (piperidine-carbamate and aryl sulfone).
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Kentaro Futatsugi, Vincent Mascitti, Cristiano R.W. Guimarães, Nao Morishita, Cuiman Cai, Michael P. DeNinno, Hua Gao, Michael D. Hamilton, Richard Hank, Anthony R. Harris, Daniel W. Kung, Sophie Y. Lavergne, Bruce A. Lefker, Michael G. Lopaze,